Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of dovitinib for advanced womb cancer
More about this trial
- see dovitinib helped women with either a normal or a changed FGFR2 gene
- learn more about the side effects
Summary of results
The trial team found that having dovitinib as the second treatment for advanced womb cancer worked a bit. But it didn’t work as well as they had hoped. And having the FGFR2 gene change didn’t affect how well treatment worked.
The researchers published these results in 2015.
About this trial
This was a phase 2 trial. 248 women joined and the researchers screened them for FGFR2. Of those:
- 27 had a change to the FGFR2 gene in their womb cancer cells
- 221 people had a normal FGFR2 gene
- 22 women with the FGFR2 gene change had dovitinib
- 31 women with a normal FGFR2 gene had dovitinib
- 7 out of the 22 women (32%) who had the FGFR2 gene change
- 9 out of the 31 women (29%) who had a normal gene
- 4.1 months in women who had the gene change
- 2.7 months in women who didn’t have the gene change
- feeling or being sick
- tiredness (fatigue)
- a blood clot on the lung
- being sick
- fluid loss (dehydration)
The trial team concluded that dovitinib worked a little bit for women with advanced womb cancer. But it didn’t work well enough to be looked at in a larger trial. Having a normal gene or a changed FGFR2 gene didn’t affect how well treatment worked.
This trial has increased knowledge about what works and what doesn’t work for advanced womb cancer.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Rebecca Kristeleit
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer